PURPOSE: Despite the lack of evidence to support its implementation in the clinical practice, induction chemotherapy (IC) before chemoradiotherapy (CRT) is often used in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). We retrospectively examined the tolerability, feasibility, and clinical outcome of both concepts in a single center analysis. PATIENTS AND METHODS: In all, 83 patients were treated between 2007 and 2010 with IC + CRT (n = 42) or CRT alone (n = 41). IC consisted of docetaxel, cisplatin and 5-fluorouracil (TPF), or cisplatin and 5-fluorouracil (PF). All patients were scheduled to receive 2 cycles of PF during concurrent CRT. Adverse events were assessed according to the common toxicity criteria of adverse events (CTCAE v. 3.0). Associations were tested using the χ² test, and survival estimates were calculated according to Kaplan-Meier. RESULTS: The median follow-up was 30.35 months (range 2.66-61.25 months). At 2 years, the overall survival rate was significantly higher for primary CRT compared to IC + CRT group (74.8 % vs. 54 %, respectively; p = 0.041). Significantly more treatment-related overall grade 4 toxicities were documented in the IC + CRT group compared to the CRT group (42.9% vs. 9.8%; p = 0.001). Renal toxicity ≥ grade 2 occurred in 52.4 % vs. 7.3 % (p < 0.001), respectively. In all, 93 % of the patients with primary CRT compared to 71 % with IC + CRT received the planned full radiotherapy dose (p = 0.012). CONCLUSION: This is, to our knowledge, the largest retrospective study to compare IC + CRT with primary CRT. IC showed high acute toxicity, compromised the feasibility of concurrent CRT, and was associated with reduced overall survival rates compared to primary CRT. The lack of clinical benefit in conjunction with the increased toxicity does not support implementation of IC.
PURPOSE: Despite the lack of evidence to support its implementation in the clinical practice, induction chemotherapy (IC) before chemoradiotherapy (CRT) is often used in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). We retrospectively examined the tolerability, feasibility, and clinical outcome of both concepts in a single center analysis. PATIENTS AND METHODS: In all, 83 patients were treated between 2007 and 2010 with IC + CRT (n = 42) or CRT alone (n = 41). IC consisted of docetaxel, cisplatin and 5-fluorouracil (TPF), or cisplatin and 5-fluorouracil (PF). All patients were scheduled to receive 2 cycles of PF during concurrent CRT. Adverse events were assessed according to the common toxicity criteria of adverse events (CTCAE v. 3.0). Associations were tested using the χ² test, and survival estimates were calculated according to Kaplan-Meier. RESULTS: The median follow-up was 30.35 months (range 2.66-61.25 months). At 2 years, the overall survival rate was significantly higher for primary CRT compared to IC + CRT group (74.8 % vs. 54 %, respectively; p = 0.041). Significantly more treatment-related overall grade 4 toxicities were documented in the IC + CRT group compared to the CRT group (42.9% vs. 9.8%; p = 0.001). Renal toxicity ≥ grade 2 occurred in 52.4 % vs. 7.3 % (p < 0.001), respectively. In all, 93 % of the patients with primary CRT compared to 71 % with IC + CRT received the planned full radiotherapy dose (p = 0.012). CONCLUSION: This is, to our knowledge, the largest retrospective study to compare IC + CRT with primary CRT. IC showed high acute toxicity, compromised the feasibility of concurrent CRT, and was associated with reduced overall survival rates compared to primary CRT. The lack of clinical benefit in conjunction with the increased toxicity does not support implementation of IC.
Authors: Volker Budach; Martin Stuschke; Wilfried Budach; Michael Baumann; Dirk Geismar; Gerhard Grabenbauer; Ingrid Lammert; Klaus Jahnke; Georg Stueben; Thomas Herrmann; Michael Bamberg; Peter Wust; Wolfgang Hinkelbein; Klaus-Dieter Wernecke Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: T G Wendt; G G Grabenbauer; C M Rödel; H J Thiel; H Aydin; R Rohloff; T P Wustrow; H Iro; C Popella; A Schalhorn Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: F Alongi; M Bignardi; I Garassino; S Pentimalli; R Cavina; P Mancosu; G Reggiori; A Poletti; D Ferrari; P Foa; A Bigoni; A Dragonetti; P Salvatori; O Spahiu; A Fogliata; L Cozzi; A Santoro; M Scorsetti Journal: Strahlenther Onkol Date: 2011-12-24 Impact factor: 3.621
Authors: J O Brömme; M Schmücking; A Arnold; R Giger; D Rauch; D Leiser; L Plasswilm; A Geretschläger; P Ghadjar; D M Aebersold Journal: Strahlenther Onkol Date: 2013-07-04 Impact factor: 3.621
Authors: D Rades; N D Seibold; A Hoffmann; M P Gebhard; F Noack; C Thorns; S E Schild Journal: Strahlenther Onkol Date: 2013-07-17 Impact factor: 3.621
Authors: Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre Journal: N Engl J Med Date: 2007-10-25 Impact factor: 91.245
Authors: Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad Journal: N Engl J Med Date: 2007-10-25 Impact factor: 91.245
Authors: D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz Journal: N Engl J Med Date: 1998-06-18 Impact factor: 91.245
Authors: Zoltán Takácsi-Nagy; Erika Hitre; Éva Remenár; Ferenc Oberna; Csaba Polgár; Tibor Major; Mária Gödény; János Fodor; Miklós Kásler Journal: Strahlenther Onkol Date: 2015-03-18 Impact factor: 3.621
Authors: Narges Tehrany; Julia Kitz; Margret Rave-Fränk; Stephan Lorenzen; Li Li; Stefan Küffer; Clemens F Hess; Peter Burfeind; Holger M Reichardt; Martin Canis; Tim Beissbarth; Hendrik A Wolff Journal: Strahlenther Onkol Date: 2015-01-10 Impact factor: 3.621